[go: up one dir, main page]

WO2004015079A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2004015079A3
WO2004015079A3 PCT/US2003/024931 US0324931W WO2004015079A3 WO 2004015079 A3 WO2004015079 A3 WO 2004015079A3 US 0324931 W US0324931 W US 0324931W WO 2004015079 A3 WO2004015079 A3 WO 2004015079A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nucleic acids
polypeptides
polypeptide
acids encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/024931
Other languages
French (fr)
Other versions
WO2004015079A2 (en
Inventor
Mei Zhong
Weizhen Ji
Xiaojia Guo
Daniel K Rieger
Muralidhara Padigaru
Rachel Malcolm
Kimberly A Spytek
David W Anderson
Linda Gorman
Elina Catterton
John R Macdougall
David J Stone
Shlomit R Edinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/236,392 external-priority patent/US20040067490A1/en
Priority claimed from US10/242,943 external-priority patent/US20030087412A1/en
Priority claimed from US10/635,149 external-priority patent/US20050049192A1/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Priority to AU2003259704A priority Critical patent/AU2003259704A1/en
Priority to JP2005506604A priority patent/JP2006515753A/en
Priority to CA002495563A priority patent/CA2495563A1/en
Priority to EP03785086A priority patent/EP1539807A4/en
Publication of WO2004015079A2 publication Critical patent/WO2004015079A2/en
Publication of WO2004015079A3 publication Critical patent/WO2004015079A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies that immunospecifically bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the novel polypeptide, polynucleotide, or antibody specific to the polypeptide. Vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same are also included. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
PCT/US2003/024931 2002-08-07 2003-08-07 Therapeutic polypeptides, nucleic acids encoding same, and methods of use Ceased WO2004015079A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003259704A AU2003259704A1 (en) 2002-08-07 2003-08-07 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2005506604A JP2006515753A (en) 2002-08-07 2003-08-07 Therapeutic polypeptides, nucleic acids encoding the same, and methods of use
CA002495563A CA2495563A1 (en) 2002-08-07 2003-08-07 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP03785086A EP1539807A4 (en) 2002-08-07 2003-08-07 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US40159702P 2002-08-07 2002-08-07
US60/401,597 2002-08-07
US40220502P 2002-08-09 2002-08-09
US40220902P 2002-08-09 2002-08-09
US60/402,209 2002-08-09
US60/402,205 2002-08-09
US40351702P 2002-08-13 2002-08-13
US40354802P 2002-08-13 2002-08-13
US60/403,517 2002-08-13
US60/403,548 2002-08-13
US40369602P 2002-08-15 2002-08-15
US60/403,696 2002-08-15
US40631802P 2002-08-26 2002-08-26
US60/406,318 2002-08-26
US40620202P 2002-08-27 2002-08-27
US60/406,202 2002-08-27
US10/236,392 2002-09-06
US10/236,392 US20040067490A1 (en) 2001-09-07 2002-09-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US10/242,943 2002-09-13
US10/242,943 US20030087412A1 (en) 1998-10-06 2002-09-13 Nlk1 protein and Nlk1 protein complexes
US42313802P 2002-11-01 2002-11-01
US60/423,138 2002-11-01
US10/635,149 US20050049192A1 (en) 1999-06-03 2003-08-06 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US10/635,149 2003-08-06

Publications (2)

Publication Number Publication Date
WO2004015079A2 WO2004015079A2 (en) 2004-02-19
WO2004015079A3 true WO2004015079A3 (en) 2004-09-02

Family

ID=31722010

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024931 Ceased WO2004015079A2 (en) 2002-08-07 2003-08-07 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (5)

Country Link
EP (1) EP1539807A4 (en)
JP (1) JP2006515753A (en)
AU (1) AU2003259704A1 (en)
CA (1) CA2495563A1 (en)
WO (1) WO2004015079A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4863452B2 (en) * 2006-03-30 2012-01-25 国立大学法人 千葉大学 Human Th1 / Th2 differentiation induction system and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021335A1 (en) * 1996-11-14 1998-05-22 Genetics Institute, Inc. Chordin compositions
WO2001064885A1 (en) * 2000-03-02 2001-09-07 Amgen, Inc. Chordin-like-2 molecules and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279473T3 (en) * 1999-03-08 2007-08-16 Genentech, Inc. TUMOR DIAGNOSIS PROCEDURE.
US20020159986A1 (en) * 2001-01-12 2002-10-31 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021335A1 (en) * 1996-11-14 1998-05-22 Genetics Institute, Inc. Chordin compositions
WO2001064885A1 (en) * 2000-03-02 2001-09-07 Amgen, Inc. Chordin-like-2 molecules and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1539807A4 *

Also Published As

Publication number Publication date
EP1539807A4 (en) 2006-09-06
AU2003259704A1 (en) 2004-02-25
JP2006515753A (en) 2006-06-08
WO2004015079A2 (en) 2004-02-19
CA2495563A1 (en) 2004-02-19
EP1539807A2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003057158A3 (en) Method of treating apoptosis and compositions thereof
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002050277A3 (en) Protein and nucleic acids encoding same
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2002098917A3 (en) Human proteins and nucleic acids encoding same
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2002081518A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2001090155A3 (en) Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
WO2002029058A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2001029217A3 (en) Novel polypeptides and polynucleotides encoding same
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002066643A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002055702A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2003031571A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003085124A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003078572A3 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003040329A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002057452A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2001046231A3 (en) Polynucleotides and polypeptides encoded thereby
WO2002068647A3 (en) Proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003259704

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2495563

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005506604

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003785086

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003785086

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003785086

Country of ref document: EP